Sana Biotechnology

SANA

Market cap $1.15B

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

Sana (SANA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sana Biotechnology, Inc. remains a Strong Buy, driven by progress in HIP-modified cell therapies for Type 1 Diabetes and B-cell-mediated disorders. Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift in treatment. Upcoming 2025 data readouts from phase 1 GLEAM (SC291, autoimmune disorders) and VIVID (SC262, B-cell malignancies) trials are key catalysts for Sana Biotechnology.

Sana Biotechnology, Inc. surged after hedge fund manager Eric Jackson called it a potential "100-bagger" due to its pioneering diabetes cell therapy. Sana Biotechnology's breakthrough islet cell therapy, using proprietary hypoimmune technology, enabled insulin production in a type 1 diabetes patient without immunosuppression. Significant challenges remain: scalable cell manufacturing, safe and scalable administration, and massive funding needs before commercial viability is achieved.

Sana Biotechnology, Inc. (NASDAQ:SANA) shares soared on Wednesday after outspoken stock promoter Eric Jackson named it as his latest potential “100-bagger.”

Sana Biotechnology, Inc. (NASDAQ:SANA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Well, hello, everyone. I'm Maxwell Skor, biotech analyst with Morgan Stanley.

Sana Biotechnology, Inc. (NASDAQ:SANA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Great. Thanks, everyone, for being here.

Sana Biotechnology, Inc. (NASDAQ:SANA ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President Thank you for being here. My name is Sam Semenkow, I'm one of the Biotech analysts here at Citi.

RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.